# PT-141 (Bremelanotide): A Central Melanocortin Receptor Agonist for Sexual Desire > PT-141 (bremelanotide) is a central melanocortin MC3R/MC4R agonist that acts in the brain on sexual desire — FDA-approved only for HSDD in premenopausal women. A cited literature digest. A composed digest of the published record: the brain-level mechanism set out in full, the one approved indication weighed against its modest measured effect, and the nausea-led tolerability cost stated plainly and cited. ## The short version PT-141 — the research name for the drug bremelanotide — is a small synthetic peptide (a short chain of amino acids) that acts on switches in the brain called melanocortin MC3R and MC4R receptors (brain switches that influence sexual desire, appetite, and skin pigment). It does not widen blood vessels the way an erection drug does; it works upstream, on the wiring of desire itself. It is approved by the FDA for exactly one use: low sexual desire that causes real personal distress in premenopausal women. Every other use — in men, for erections, after menopause — is off-label and, in the published research, early-stage at best. ## What the PT-141 record actually establishes PT-141 (bremelanotide) is a synthetic cyclic heptapeptide — a ring of seven amino acids — modelled on the body's own melanocortin signal, alpha-MSH (alpha-melanocyte-stimulating hormone, a natural brain peptide that switches melanocortin receptors on) [1]. Where a PDE-5 inhibitor (the familiar class of erection medicines, which act on blood vessels) works at the periphery on vascular smooth muscle, PT-141 works centrally, in the hypothalamus and limbic system, on the circuitry that governs sexual motivation itself [1] [11]. Its standing in the record is unusually precise, and it is worth stating without ornament: PT-141 is a real, approved prescription drug — but its approval covers a single indication. In June 2019 the United States approved bremelanotide injection for acquired, generalized hypoactive sexual desire disorder (HSDD — persistent, distressing low sexual desire not explained by another condition) in premenopausal women [3] [11]. That is the whole of the licence. The compound's earlier and more famous association — [PT-141 for men](/research), erectile response — never reached approval and remains investigational [1]. The foundations are well laid. Systemic PT-141 produced erections in rats and nonhuman primates and activated hypothalamic neurons, and produced rapid, dose-dependent erectile activity in men with erectile dysfunction in early work [1]. In female rats it selectively raised solicitational, desire-driven behaviour without altering reflexive responses or general movement — the first agent reported to act on appetitive female sexual behaviour [2]. The human desire indication followed from there, by way of [the RECONNECT Phase 3 trials](/research) [3]. ## PT-141 Peptide: Structure and Identity As a PT-141 peptide, the molecule is a cyclic seven-amino-acid lactam, sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a bridge tying the Asp and Lys side chains into a ring [1]. The ring matters: cyclisation makes it sturdier than the loose, linear melanocortin peptides, which is part of why it survives in the body well enough to be dosed by injection [1] [11]. Its identifiers are settled. Bremelanotide is the international nonproprietary name (INN); PT-141 is the development designation; the two name one compound [3]. Molecular formula C50H68N14O10, molecular weight 1025.2 Da, CAS 189691-06-3, FDA UNII 6Y24O4F37N, DrugBank DB12420, approved under NDA 210557 [11]. It is a near relative of another melanocortin agonist, melanotan II, differing chiefly at the C-terminus, where an amide is replaced by a carboxylic acid [1]. What it is not is as instructive as what it is. PT-141 does not act through the hypothalamic-pituitary-gonadal axis and does not raise testosterone directly; it is not a hormone replacement and not a PDE-5 inhibitor [1] [11]. Material sold as 'PT-141 research chemical' is laboratory material with no regulatory oversight of identity, purity, or concentration — it is not the approved finished medicine [11]. ## A first-in-class signal, and what came before it PT-141 did not arrive from nowhere. It descends from the body's own melanocortin system — alpha-MSH, cleaved from the precursor protein pro-opiomelanocortin (POMC), is the natural ligand these receptors evolved to read [1]. The synthetic line that led here ran through melanotan II, a close melanocortin relative; PT-141 differs from it chiefly at one end of the molecule, where an amide is replaced by a carboxylic acid [1]. That small chemical edit shifted the emphasis of the pharmacology toward the central sexual-desire effect that became its reason for being. What made it notable in sexual medicine was not potency but place. In female rats it was the first pharmacological agent reported to act on appetitive, desire-driven sexual behaviour rather than reflexive response [2]. In people, it became the first centrally-acting melanocortin agonist approved for a sexual-desire indication [3] [12]. 'First-in-class' is a claim about novelty of mechanism, not size of effect — and on the second count, as the trials record, the measured benefit is modest [3]. The receptor family also explains the compound's edges. Because the same melanocortin system reaches appetite circuits (through MC4R) and pigment cells (through MC1R), weight and skin effects sit at the margins of its pharmacology — not as accidents, but as predictable consequences of acting on a broadly-wired signalling family [11]. ## Where the desire signal is made PT-141's effect begins at the melanocortin 4 receptor (MC4R), the central receptor most densely expressed in the hypothalamic and limbic circuits that set sexual motivation; the melanocortin 3 receptor (MC3R) contributes as a secondary central pathway [1]. By stimulating MC4R in regions such as the medial preoptic area — a patch of the anterior hypothalamus long tied to sexual motivation — it is thought to engage dopaminergic signalling, the brain's appetitive, wanting circuitry [11]. The neuroimaging bears this out. In a placebo-controlled crossover fMRI study of 31 premenopausal women with HSDD, MC4R agonism raised sexual desire for up to 24 hours and altered how the brain processed erotic stimuli — enhanced amygdala-insula connectivity, shifted cerebellar and supplementary-motor activity [5]. The mechanism is the story; the full account of [how PT-141 works](/how-it-works) at the receptor and circuit level — the complete [PT-141 mechanism of action](/how-it-works) — is set out on its own page. ## How this digest reads the record Three things are true at once, and an honest digest holds all three. The mechanism is genuinely novel and reasonably well mapped. The one approved use rests on two completed Phase 3 trials. And the measured benefit, in that approved population, is real but modest — and it carries a tolerability cost that is itself well documented [3] [4]. This site keeps the cited, peer-reviewed record and the unverified community accounts on separate sheets, and labels them as such. The clinical claims here are drawn from the trials and the prescribing information and carry citations; the [PT-141 side effects](/side-effects) page sets out the tolerability picture — nausea, flushing, headache, a transient blood-pressure caution, focal skin darkening — in full, alongside a clearly-marked field-reports section that is not evidence. For the underlying sources, see the [study references](/references). --- A gilt-on-midnight reading of the PT-141 (bremelanotide) record — the central-desire mechanism set out in full, the one approved indication weighed against its modest measured effect, and the nausea-led tolerability cost stated first, with the unverified field reports kept to their own silvered margin; no clinic behind the gold and nothing here prescribed, dispensed, or sold.